Manufacturing Expertise Antibody-Drug Conjugate (ADC)

High purity and structural consistency are essential for conjugation. A key advantage of Avid’s platform is the ability to provide a seamless transition from mAb production through conjugation and purification within a single organization. This integrated approach reduces technology transfer risks, shortens development timelines, and helps accelerate progression toward regulatory submissions, clinical supply, and eventual commercial manufacturing.

Yes, Avid has extensive in-house capabilities and experienced technical staff supporting ADC development programs. We have significant expertise in process development for non-potent payload conjugation, conjugate purification, and analytical support to enable robust and scalable manufacturing processes.

Avid’s CGMP manufacturing platform utilizes validated and scalable single-use systems, allowing efficient production while maintaining the flexibility required for ADC programs. Our team can support process development, technology transfer, CGMP manufacturing, and purification of ADCs containing non-potent payloads, providing an integrated solution from development through clinical supply.